MX342735B - Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo. - Google Patents

Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.

Info

Publication number
MX342735B
MX342735B MX2014004870A MX2014004870A MX342735B MX 342735 B MX342735 B MX 342735B MX 2014004870 A MX2014004870 A MX 2014004870A MX 2014004870 A MX2014004870 A MX 2014004870A MX 342735 B MX342735 B MX 342735B
Authority
MX
Mexico
Prior art keywords
methods
hyaluronan
hyaluronan agent
agent therapy
companion diagnostic
Prior art date
Application number
MX2014004870A
Other languages
English (en)
Other versions
MX2014004870A (es
Inventor
Jiang Ping
H Shepard Michael
Huang Lei
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halozyme Inc filed Critical Halozyme Inc
Publication of MX2014004870A publication Critical patent/MX2014004870A/es
Publication of MX342735B publication Critical patent/MX342735B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

La presente invención se refiere a métodos y agentes de diagnóstico para identificación de sujetos para tratamiento de cáncer con un agente anti-hialuronano, tal como una enzima degradadora del hialuronano. Se proporcionan los agentes de diagnóstico para la detección y cuantificación del hialuronano en una muestra biológica y el monitoreo del tratamiento del cáncer con un agente anti-hialuronano, por ejemplo una enzima degradadora de hialuronano. También se proporcionan combinaciones y kits para uso en la práctica de los métodos.
MX2014004870A 2011-10-24 2012-10-24 Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo. MX342735B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161628187P 2011-10-24 2011-10-24
US201161559011P 2011-11-11 2011-11-11
US201161630765P 2011-12-16 2011-12-16
US201261714700P 2012-10-16 2012-10-16
PCT/US2012/061743 WO2013063155A2 (en) 2011-10-24 2012-10-24 Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2014004870A MX2014004870A (es) 2014-10-14
MX342735B true MX342735B (es) 2016-10-07

Family

ID=47116517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004870A MX342735B (es) 2011-10-24 2012-10-24 Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.

Country Status (14)

Country Link
US (2) US8846034B2 (es)
EP (2) EP2771028A2 (es)
JP (1) JP6162707B2 (es)
KR (1) KR101828828B1 (es)
CN (1) CN104093415B (es)
AU (1) AU2012328880B2 (es)
BR (1) BR112014009797A2 (es)
CA (1) CA2853358A1 (es)
EA (1) EA030440B1 (es)
HK (2) HK1202802A1 (es)
IL (1) IL232229B (es)
MX (1) MX342735B (es)
SG (1) SG11201401797TA (es)
WO (1) WO2013063155A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942588B (zh) 2003-03-05 2013-06-12 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
NZ593641A (en) 2008-12-09 2013-01-25 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
CA2806058C (en) 2010-07-20 2016-09-13 Halozyme, Inc. Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
CN104093415B (zh) 2011-10-24 2017-04-05 哈洛齐梅公司 抗乙酰透明质酸剂疗法的同伴诊断剂及其使用方法
EP2797622B1 (en) 2011-12-30 2016-10-12 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
US9278124B2 (en) * 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
MX2015007931A (es) * 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
US10537648B2 (en) 2014-06-25 2020-01-21 Novartis Ag Compositions and methods for visualization of the vitreous
WO2015198240A2 (en) * 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) * 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
JP6355842B2 (ja) 2014-07-10 2018-07-11 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ マルチドラッグ送達システム及びその使用
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
EP3356863A4 (en) 2015-10-02 2019-06-12 Southern Research Institute IMAGING PHANTOM AND ITS SYSTEMS AND METHODS OF USE
KR101698003B1 (ko) * 2016-06-20 2017-01-19 여오영 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
SI3481859T1 (sl) 2016-07-07 2022-07-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe
JP2019533149A (ja) * 2016-09-23 2019-11-14 ヴェンタナ メディカル システムズ， インク． 腫瘍試料中の細胞外マトリックスバイオマーカーをスコアリングするための方法及びシステム
US10994017B2 (en) * 2016-12-02 2021-05-04 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20190391151A1 (en) * 2017-03-07 2019-12-26 Elypta Ab Cancer biomarkers
CN110004105B (zh) * 2018-01-05 2023-09-29 上海普佑生物医药有限公司 一种蛋白在细胞培养中的应用
US20220202899A1 (en) * 2019-04-30 2022-06-30 Haplnscience inc. Composition for prevention or treatment of hair loss including hapln1
MA55883A (fr) * 2019-05-07 2022-03-16 Genzyme Corp Procédés de quantification de la concentration en médicament dans une composition de promédicament
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102166453B1 (ko) * 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
CN111218452B (zh) * 2020-02-25 2022-11-15 芜湖天明生物技术有限公司 一种重组人tsg-6基因、重组人tsg-6蛋白标准品及其制备方法和应用
BR112022018741A2 (pt) * 2020-04-03 2022-11-01 Standard Of Care Corp Composições de hialuronidase e/ou 4-metilumbeliferona aerossolizadas e métodos de uso das mesmas para tratar doenças ou distúrbios respiratórios
CN111449684B (zh) * 2020-04-09 2023-05-05 济南康硕生物技术有限公司 心脏超声标准扫查切面快速获取方法及系统
US11883245B2 (en) * 2021-03-22 2024-01-30 Verb Surgical Inc. Deep-learning-based real-time remaining surgery duration (RSD) estimation
MX2024009755A (es) * 2022-02-10 2024-08-20 Kodiak Sciences Inc Metodos de purificacion de un producto.
CN117074683A (zh) * 2022-05-09 2023-11-17 四川大学 检测c1qbp蛋白表达水平的试剂在制备口腔癌筛查或预后试剂盒中的用途
CN117664885B (zh) * 2023-11-28 2024-05-07 中国计量科学研究院 一种织物中透明质酸含量的定量检测方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2488564A (en) 1947-06-03 1949-11-22 Orthe Pharmaecutlcal Corp Preparation of hyaluronidase
US2488565A (en) 1947-06-04 1949-11-22 Ortho Pharma Corp Preparation of hyaluronidase
US2676139A (en) 1950-09-01 1954-04-20 American Home Prod Hyaluronidase
US2808362A (en) 1952-05-02 1957-10-01 Armour & Co Preparation of hyaluronidase
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
US2806815A (en) 1955-04-12 1957-09-17 Ortho Pharma Corp Stabilized hyaluronidase
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
NO173355C (no) 1987-03-03 1993-12-01 Chugai Pharmaceutical Co Ltd Fremgangsm}te og selektiv bestemmelse av en h!ymolekylvekts hyaluronsyre og reagenssett for utf!relse av fremgangsm}ten
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE136315T1 (de) 1989-05-27 1996-04-15 Sumitomo Pharma Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine.
ATE193551T1 (de) 1991-03-18 2000-06-15 Scripps Research Inst Oligosaccharide als enzymsubstrate und - inhibitoren: verfahren und zusammensetzungen
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5872094A (en) 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
KR100203824B1 (ko) 1994-03-31 1999-06-15 스티븐 엠. 오드리 거핵구 성장 및 분화를 자극하기 위한 조성물 및방법
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6103525A (en) 1996-10-17 2000-08-15 The Regents Of The University Of California Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
CA2237051A1 (en) 1997-12-19 1999-06-19 Eva A. Turley Enhanced affinity hyaluronan binding peptides
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
WO1999045942A1 (en) 1998-03-13 1999-09-16 Entremed, Inc. Metastatin and hyaluronate binding proteins and methods of use
AU5039399A (en) 1998-07-03 2000-01-24 Neles Field Controls Oy Method and arrangement for measuring fluid
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6872546B1 (en) 1998-12-23 2005-03-29 Human Genome Sciences, Inc. Hyaluronan-binding proteins and encoding genes
US6852696B2 (en) * 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
ATE368125T1 (de) 1999-07-23 2007-08-15 Forensic Science Service Ltd Verfahren zur erkennung von einzel-nukleotid- polymorphismen
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1284987B1 (en) 2000-05-16 2007-07-18 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
ATE505204T1 (de) 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
WO2004043397A2 (en) 2002-11-12 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of rheumatoid arthritis
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
JP5036302B2 (ja) 2003-02-10 2012-09-26 ティオー − ビービービー ホールディング ベスローテン フェンノートシャップ 炎症状態下に血液脳関門で示差的（ｄｉｆｆｅｒｅｎｔｉａｌｌｙ）に発現される核酸
CN102139114A (zh) 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
US7257268B2 (en) 2003-02-28 2007-08-14 Aperio Technologies, Inc. Systems and methods for image pattern recognition
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN1942588B (zh) 2003-03-05 2013-06-12 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
MXPA05007628A (es) 2003-05-23 2005-10-19 Nektar Therapeutics Al Corp Derivados de polimeros que tienen arreglos de atomos particulares.
US7662929B2 (en) 2003-10-10 2010-02-16 Alchemia Oncology Pty Limited Antibody that specifically binds hyaluronan synthase
ZA200604864B (en) 2003-12-19 2007-10-31 Genentech Inc Monovalent antibody fragments useful as therapeutics
WO2005118799A1 (en) 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
GB0408351D0 (en) 2004-04-15 2004-05-19 Plasso Technology Ltd Reversible binding surface
US7112687B2 (en) 2004-07-15 2006-09-26 Indena, S.P.A. Methods for obtaining paclitaxel from taxus plants
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
JP5140579B2 (ja) 2005-06-08 2013-02-06 カンジェーン コーポレイション 病原菌に対する生体防御を増強するヒアルロン酸結合性ペプチド
AU2007249805B2 (en) 2006-05-12 2013-01-10 University Of Miami Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma
US8023714B2 (en) 2007-06-06 2011-09-20 Aperio Technologies, Inc. System and method for assessing image interpretability in anatomic pathology
FI4269578T3 (fi) 2008-03-06 2024-06-07 Halozyme Inc Liukoisen hyaluronidaasin suurimittainen tuotanto
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2270145B1 (en) 2008-04-15 2013-01-16 Wako Pure Chemical Industries, Ltd. Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EP2335221B8 (en) 2008-09-16 2016-05-25 Novartis AG Reproducible quantification of biomarker expression
NZ593641A (en) 2008-12-09 2013-01-25 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
ES2559029T3 (es) 2009-04-24 2016-02-10 Tissue Tech, Inc. Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
WO2011034604A2 (en) 2009-09-17 2011-03-24 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US20110111435A1 (en) 2009-11-06 2011-05-12 SlidePath Limited Detecting Cell Surface Markers
CN101899118B (zh) * 2010-04-22 2012-05-30 曹利民 一种融合蛋白HABP-mKate及其制备方法和应用
CA2806058C (en) 2010-07-20 2016-09-13 Halozyme, Inc. Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
EP2720713A2 (en) 2011-06-17 2014-04-23 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
CN104093415B (zh) * 2011-10-24 2017-04-05 哈洛齐梅公司 抗乙酰透明质酸剂疗法的同伴诊断剂及其使用方法
EP2797622B1 (en) 2011-12-30 2016-10-12 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途

Also Published As

Publication number Publication date
US20140348817A1 (en) 2014-11-27
EP2771028A2 (en) 2014-09-03
KR101828828B1 (ko) 2018-03-29
HK1213206A1 (zh) 2016-06-30
CN104093415B (zh) 2017-04-05
EA030440B1 (ru) 2018-08-31
EP2915542A1 (en) 2015-09-09
US20150218544A9 (en) 2015-08-06
KR20140092851A (ko) 2014-07-24
NZ624489A (en) 2016-02-26
SG11201401797TA (en) 2014-09-26
CN104093415A (zh) 2014-10-08
MX2014004870A (es) 2014-10-14
AU2012328880B2 (en) 2017-02-23
US20130202583A1 (en) 2013-08-08
WO2013063155A2 (en) 2013-05-02
HK1202802A1 (en) 2015-10-09
CA2853358A1 (en) 2013-05-02
US9458442B2 (en) 2016-10-04
BR112014009797A2 (pt) 2020-10-27
WO2013063155A3 (en) 2013-07-11
JP2014532865A (ja) 2014-12-08
US8846034B2 (en) 2014-09-30
IL232229A0 (en) 2014-06-30
EA201400491A1 (ru) 2015-08-31
IL232229B (en) 2019-05-30
JP6162707B2 (ja) 2017-07-12

Similar Documents

Publication Publication Date Title
MX342735B (es) Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
EP3865135A3 (en) Neuroactive steroids for use in therapy
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
AU2011260390A8 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2013138522A3 (en) Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
GB2519906A (en) Methods and systems for detecting biological components
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2010091049A3 (en) Diagnosis and treatment of cancer
IL222251A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
EP3186397A4 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
CA2815892C (en) Analytical methods and arrays for use in the same
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
AU2013231230A8 (en) Method for selecting or identifying a subject for V1B antagonist therapy
WO2016168359A8 (en) Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
GB2465907A (en) VHZ for diagnosis and treatment of cancer
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
EP4328324A3 (en) Methods of diagnosing epilepsy

Legal Events

Date Code Title Description
FG Grant or registration